

Ayudas Proyectos Generales AECC 2023

Adjudicatarios

Dr. Luis Álvarez

Centro Nacional de Investigaciones
Oncológicas (CNIO)

Generation of dual STAb-T cells targeting intracellular and cell surface tumor-associated antigens to overcome the clonal heterogeneity of solid tumors

Dr. Toni Gabaldón

Instituto de Investigación Biomédica (IRB
Barcelona)

Metagenomic profiling from fecal immunochemical test tubes to identify early players and diagnostic markers in colorectal cancer

Dr. Antoni Celia

Hospital del Mar Research Institute

Sensitizing ER+ breast cancer to immune-checkpoint blockade therapy

Dr. Miguel Quintela-Fandino

Centro Nacional de Investigaciones
Oncológicas (CNIO)

Assessment of the stimulated immune signaling pathways status and its relationship with response to immunotherapies and ADCs in triple negative breast cancer

Dr. Pablo Menéndez

Instituto de Investigación Contra la
Leucemia Josep Carreras (IJC)

Next generation, off-the-shelf, CD1a/CCR9-directed dual CAR immunotherapy for relapse/refractory T-cell acute lymphoblastic leukemia

Dr. Jose Ignacio Martín

Fundació Clínic per a la Recerca
Biomèdica-IDIBAPS

Exploring the biological and clinical impact of de novo chromatin activation in chronic lymphocyt leukemia

Dr. Mario Fernández

Centro de Investigación de
Nanomateriales y Nanotecnología (CINN)

Machine learning discovery and integration of multi-omics biomarkers to prevent unexpected recurrence and to avoid unnecessary chemotherapy in women with endometrial cancer

Dra. Aura Carreira

Centro de Biología Molecular "Severo Ochoa" (CBM-CSIC)

Development of BRCA2-PARP1 interaction inhibitors (B-Pi) as radiosensitizers for homologous recombination proficient breast tumors

Dr. Miguel López

Centro Singular de Investigación en Medicina Molecular y Enfermedades Crónicas (CIMUS)

sEVs as an innovative nanomedicine approach to treat cancer cachexia by targeting the hypothalamus

Dr. Raul Miguel Luque

Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC)

Identification of novel diagnostic, prognostic, and/or therapeutic targets in oligodendroglioma associated with the dysregulation of gene expression and genomic instability mechanisms